Maintaining Antiviral Efficacy after Switching to Generic Entecavir 1 mg for Antiviral-resistant Chronic Hepatitis B
| Autor: | Young Eun Ahn, Sang Jun Suh, Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim |
|---|---|
| Jazyk: | English<br />Korean |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | The Korean Journal of Gastroenterology, Vol 77, Iss 1, Pp 22-29 (2021) |
| Druh dokumentu: | article |
| ISSN: | 1598-9992 2233-6869 |
| DOI: | 10.4166/kjg.2020.0144 |
| Popis: | Background/Aims: Clinical equivalence of generic antiviral agents for chronic hepatitis B (CHB) has not been demonstrated, particularly in cases with previous antiviral resistance. Entecavir 1 mg is prescribed frequently as a mono- or combination therapy in antiviral-resistant CHB patients. This study evaluated the efficacy and safety of switching to generic entecavir 1 mg (Baracle®) in CHB patients taking brand-name entecavir 1 mg (Baraclude®) alone or in combination with other nucleotide analogs after the development of antiviral resistance. Methods: This study was a single-arm prospective study. The primary endpoint was undetectable HBV DNA ( |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|